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represented by 15,332 survey participants. Participants were classiﬁed according to 
CVD risk as diseased (history of coronary heart disease, angina, and/or myocardial 
infarction), at-risk (history of hyperlipidemia, hypertension, and/or diabetes mellitus), 
or low-risk (no history of any conditions). They were also classiﬁed according to the 
reported use of single-ingredient DSs including niacin, coenzyme Q10, ﬁsh oil, garlic, 
vitamin C, and vitamin E during the month prior to survey. Tests of moderation and 
confounding by age were performed. RESULTS: The prevalence of use of any of the 
six DSs increased with age. Odds ratios for any DS use for the at-risk and diseased 
groups, relative to the low-risk group, were 1.91 (95% CI: 1.67–2.17) and 2.25 (95% 
CI: 1.88–2.69), respectively. With adjustment for age, these became 1.32 (95% CI: 
1.15–1.52) and 1.20 (95% CI: 0.99–1.44), respectively. There was no evidence of 
moderation (p = 0.123), though confounding was present (p < 0.001). CONCLU-
SIONS: There is a potential for residual confounding by age in studies of CVD risk 
and DS use. After adequately controlling for age in this study, the relationship between 
CVD risk and DS use was greatly attenuated. The ﬁndings indicated different patterns 
of responses to cardiovascular disease risk between younger adults and older ones in 
terms of DS consumption. Awareness of the confounding effect of age in the associa-
tion of CVD risk and DS use should be noted in clinical practice and health 
promotion.
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OBJECTIVES: To evaluate the long-term cost-effectiveness of switching from insulin 
Glargine (IGla) to Insulin Detemir (IDet) in type 2 diabetes patients in the setting of 
Chinese tier 3 hospitals. METHODS: A published and validated computer simulation 
model of diabetes (the CORE Diabetes Model) was used to make the long- term (30 
years) projection of health economic outcomes. Patient demographic information and 
clinical endpoints were derived from a subgroup analysis of the PREDICTIVE study. 
PREDICTIVE was a large, multi-centre, 6 months observational study assessing the 
safety and efﬁcacy of IDet in everyday clinical practice. HbA1c was reduced of 0.59 
% by switching from IGla to IDet. Baseline risk factors and racial characteristic data 
were obtained from Chinese cohort studies. The market retail prices of medications 
were calculated to estimate treatment costs. The diabetes management and complica-
tions costs were obtained from Chinese published data and adjusted to 2009 values 
using the Chinese Consumer Price Index. An annual discounting rate of 3% was used 
for both health and cost outcomes according to the recommendation of Chinese 
Pharmacoeconomics guideline. One-way sensitivities analysis was performed and illus-
trated that the results were robust. RESULTS: Conversion to IDet from IGla was 
projected to improve patient life expectancy by 0.09 year and 0.36 quality adjusted 
life years (QALYs). Treatment costs, and management costs were increased of 4,004 
(84,047 vs 80,043), 243 (28,913 vs 28,670) Chinese Yuan (CNY) respectively. 
However, the costs of complications including CVD, renal, ulcer/amputation/neuropa-
thy, eye and hypoglycaemia events were reduced by 4,931 CNY (89,628 vs 94,559), 
resulting in a total direct medical cost saving of 684 CNY when converting to IDet. 
CONCLUSIONS: Conversion to IDet from an IGla regimen improved life-expectancy 
and was a cost-saving treatment approach in a Chinese setting.
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OBJECTIVES: Pulmonary arterial hypertension (PAH) is a clinical condition that 
causes decreased exercise tolerance and heart failure. The aim of this study was to 
assess the cost-effectiveness of different drugs to manage PAH in adult, functional 
class III, patients, who have failed previously to calcioantagonists, from the health 
care payer’s perspective. METHODS: A ﬁve-state Markov model was performed to 
estimate one year costs and health consequences (1-month cycles). Effectiveness mea-
sures were quality-adjusted life years (QALY’s) gained, as well as reduction in hospital 
length of stay (LOS) and discontinuation rate due to adverse events. Transition prob-
abilities were obtained from a meta-analysis involving national and international 
published literature. Doses of comparators used in the assessment were sildenaﬁl 
(60 mg/day); bosentan (250 mg/day); sitaxsentan (100 mg/day) and ambrisentan 
(5 mg/day, reference alternative). Resource use and costs were obtained from hospital 
records (n = 110) from the Social Security Mexican Institute. Costs include hospital 
stay, laboratory and respiratory function tests, imagenology, drugs and adverse events 
management. The model was validated according to international guidelines. Sensitiv-
ity analyses were performed employing bootstrapping techniques and acceptability 
curves were constructed. RESULTS: Per patient associated costs for sildenaﬁl, bosen-
tan, sitaxsentan and ambrisentan were [CI 95%]: US$16,840 [US$16,590–US$17,176], 
US$38,068 [US$37,725–US$38,497], US$40,203 [US$39,888–US$40,647] and 
US$26,146 [US$25,898–US$26,479], respectively. Sildenaﬁl is associated to the 
highest gain in QALY’s: 0.1 [−0.01–0.22], as well as to the main reduction in discon-
tinuation rate: 89.25 [89.11%-89.4%] and reduction in LOS: 8.64 days [8.53 days–
8.75 days], respectively. In consequence, sildenaﬁl represents the most attractive 
therapy to manage PHA in terms of cost-effectiveness. CONCLUSIONS: In the 
Mexican institutional setting, sildenaﬁl demonstrated to be a cost-saving therapy to 
manage PHA in adult, functional class III patients. These results should be taken into 
account by Mexican health professionals to generate efﬁcient resource allocation 
strategies.
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OBJECTIVES: Severe abdominal sepsis and septic shock (SAS-SS) are common prob-
lems in intensive care units (ICU), and carry high mortality. This study assessed the 
cost-effectiveness of Polymyxin B immobilized ﬁber column (PMX) plus conventional 
therapy (CT) (PMX-CT) versus CT alone, for SAS-SS, in the perspective of the Italian 
NHS (hospital). METHODS: This study was a retrospective cost-effectiveness analysis 
(CEA) with clinical efﬁcacy and consumption of resources collected alongside an RCT 
(Cruz et al. JAMA 2009). 64 SAS-SS patients were enrolled following emergency 
surgery for intra-abdominal infection in 10 tertiary care ICUs, from 12/2004 
to12/2007. Costs included: hospital days, ICU days; catecholamine treatment days; 
renal replacement therapy (RRT) days; mechanical ventilation treatment (MVT) days; 
use of PMX device. Resources were valued using published tariffs and market values. 
All-cause hospital mortality was extrapolated to survival (expected life-years per 
patient/arm): for each survivor average life expectancy (in years) by age and sex was 
retrieved from National Life Tables; for deceased patients, only the number of survival 
days as reported in the CRF, was retained. Per patient survival was then weighed using 
a predicted death rate based on individual Apache II scores, to account for disease 
severity. Univariate sensitivity analyses on costs and outcomes and 2000 Bootstrap 
simulations were run to test CEA’s results. RESULTS: Based on the expected number 
of survival years (PMX-CT 8.24/patient, CT 4.69/patient), the mean difference in 
survival yielded an expected increase of 3.55LYG/patient for PMX-CT, at the addi-
tional cost of 313,411/patient with a mean ICER of 33,774/LYG and a median ICER 
of 32,776/LYG. Results of the base-case CEA were conﬁrmed by all sensitivity analyses 
with ICER values always well below commonly accepted value thresholds.CONCLU-
SIONS: PMX-CT vs. CT is a cost-effective intervention for treatment of severe abdom-
inal sepsis and septic shock and should be considered for use in the Italian NHS’ 
hospital setting.
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OBJECTIVES: Under the circumstances of a severe pandemic and constrained research 
and manufacturing capacity, the need to appropriately deploy vaccination stockpiles 
becomes critical. The objective of this study was to provide insight into the most 
cost-effective vaccination strategy when under constrained circumstances. METHODS: 
A deterministic and compartmental SIR (Susceptible-Infected-Removed) cost-effective-
ness model was developed from a US CDC perspective using Microsoft Excel. The 
model consists of 6 distinct age groups, integrated by a contact matrix. The infectivity 
of the pandemic was based on reported CDC estimates, with the model calibrated 
accordingly. A 75% vaccination efﬁcacy was used, consistent with previous studies. 
Under the assumption of stockpiling 50 million doses of vaccine, vaccination strategies 
were assessed in terms of infections avoided during the estimated 17 month period of 
the pandemic. The scenarios included strategies targeted to speciﬁc age groups: indi-
vidually targeted age groups, groups under 20, over 20, 20–59 and 0–12 and 60+ 
combined. Costs were limited to vaccine acquisition, with the total rate of vaccination 
per day estimated at 741,935. For the base case, we initiate the pandemic in May 
2009 and began vaccination in October. Sensitivity analysis on the initiation of vac-
cination was also assessed. RESULTS: With no vaccination, a basic reproduction 
number of 1.3 and infectious period of 4.5 days yielded an attack rate of 27.7%.The 
cost-effectiveness of targeted vaccination ranged from $4.87 (13–19 years) to $67.05 
(65+) per infection avoided. Under the criteria of exhausting vaccine supplies, the most 
cost-effective strategy was to target those under 20 years old ($10.77 per infection 
avoided). Initiating vaccination earlier during a pandemic marginally improved cost-
effectiveness, while delayed vaccination resulted in substantially reduced cost-effec-
tiveness. CONCLUSIONS: Administering vaccinations to those aged under 20 years 
is the most cost-effective strategy. All vaccination policies initiated after the peak of 
the pandemic, were less cost-effective.
